Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blue dye and red light: a new hope for itchy skin?

NCT ID NCT03068208

Symptom relief Sponsor: Chulalongkorn University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tested whether applying methylene blue (a dye) to skin lesions and then shining red light on them could improve skin roughness in people with lichen amyloidosis, a condition causing itchy, bumpy patches. Fifteen Asian adults with the condition received the treatment. The main goal was to see if skin texture got better.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
methylene blue
What this could lead to
If it works, this could offer a new, non-invasive way to improve skin texture for people with lichen amyloidosis.
What could go wrong
This is a very small pilot study with only 15 participants, so results may not apply to everyone. The treatment is experimental and may not provide lasting improvement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

15 people

The number who actually took part.

Started

May 2022

Finished

Jun 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients, aged \> 18 years old with lichen amyloidosis diagnosed by using clinical presentation and pathological findings. Exclusion Criteria: * Those with systemic disease associated cutaneous amyloidosis * Pregnancy or lactating woman * Those who are allergic to urea, olive oil * Those who are photosensitive to ultraviolet radiation * Those who had been previously treated with any of which -medications, radiation, laser within 3 months and 1 month for topical therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lichen amyloidosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lichen amyloidosis primary cutaneous amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lichen amyloidosis

Contacts and locations

Locations

  • King Chulalongkorn Memorial Hospital

    Bangkok, Bangkok, 10330, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.